Estrofem® was especially developed and indicated for the treatment of oestrogen deficiency symptoms in women without a uterus, with effective symptom relief and good tolerability (continuous therapy with calendar pack of 28 tablets containing 1mg 17b-oestradiol). As there is no increased risk of developing cancer of the uterus lining in women without a uterus, they need not to take an additional progestogen. The drug is available in different dosages because a standardised unique dose is not optimal for every woman. Studies have demonstrated that after four weeks of treatment there is a significant reduction in hot flushes and other menopausal complaints. The administration of Estrofem® results in a significant increase of bone density.
Estrofem® is an oestrogen only treatment for effective symptom relief and one of the options for osteoporosis prevention in hysterectomised women.
Promotes growth and development of female reproductive system and secondary sex characteristics; affects release of pituitary gonadotropins; inhibits ovulation and prevents postpartum breast engorgement; conserves calcium and phosphorous and encourages bone formation; overrides stimulatory effects of testosterone.
Click to view the video